Anteris Technologies Global Corp., a structural heart company, develops and commercializes minimally invasive medical devices to treat heart valve diseases. It offers the DurAVR transcatheter heart valve system, a novel transcatheter aortic valve for the treatment of aortic stenosis that is shaped to mimic the performance of a healthy human aortic valve. The company also develops ADAPT anti-calcification tissue, an anti-calcification preparation that transforms xenograft tissue into durable bioscaffolds that are used to mimic human tissue for surgical repair in multiple settings, including aortic valve replacement; and ComASUR delivery system, a physician-developed balloon expandable delivery system that contains a reinforced steerable catheter for a precise deflection through the heart anatomy in a controlled manner to avoid damage to the aorta. Anteris Technologies Global Corp. is based in Toowong, Australia.
Metrics to compare | AVR | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipAVRPeersSector | |
|---|---|---|---|---|
P/E Ratio | −2.5x | −5.7x | −0.6x | |
PEG Ratio | −0.07 | −0.05 | 0.00 | |
Price/Book | 57.5x | 3.4x | 2.6x | |
Price / LTM Sales | 99.4x | 3.3x | 3.2x | |
Upside (Analyst Target) | 228.9% | 51.1% | 41.8% | |
Fair Value Upside | Unlock | 16.4% | 5.1% | Unlock |